Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07423533RecruitingPhase 2
GenSci120 injection for moderate to severe rheumatoid arthritis
This trial tests a new injection called GenSci120 for people with moderate to severe rheumatoid arthritis who haven't improved enough after trying at least one standard arthritis medication. The goal is to see if this treatment can help reduce joint pain and swelling.
Beijing, Beijing MunicipalityAges 18–70 - NCT07418736RecruitingPhase 2
CM326 for moderate to severe COPD
This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.
Beijing, Beijing MunicipalityAges 40–85 - NCT07412860Recruiting
Eye drop test for moderate to severe dry eye
This trial tests a new eye drop (FBV_01) compared to a standard hyaluronic acid eye drop for people with moderate to severe dry eye. The goal is to see if the new drop provides better relief.
Cagliari, CAAges 18 years+ - NCT07408024RecruitingPhase 2
TollB-001 tablets for moderate to severe rheumatoid arthritis
This trial tests an experimental tablet, TollB-001, for people with moderate to severe rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–70 - NCT07413172RecruitingPhase 2
Testing serum tears for severe dry eye
This study tests whether eye drops made from your own blood serum (with a natural lubricant) can relieve moderate-to-severe dry eye better than a standard salt solution. If you have dry eye from certain immune conditions or nerve damage, this may help find a more effective treatment.
Miami, FloridaAges 18 years+ - NCT07402551RecruitingPhase 2
Testing RC1416 injection for COPD flare-ups
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
Hefei, AnhuiAges 40–85 - NCT07403487RecruitingPhase 2
Study of RC1416 injection for moderate-to-severe asthma
This study tests a new injected medicine, RC1416, for people with moderate-to-severe asthma that is not well controlled with their current inhalers. It aims to see if the treatment can reduce asthma attacks and improve breathing.
Anqing, AnhuiAges 18–75 - NCT07399067RecruitingPhase 2
Testing IBI3002 for moderate to severe eczema
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Beijing, Beijing MunicipalityAges 18–75 - NCT06320041RecruitingPhase 4
Oliceridine for pain after orthopedic surgery
This trial tests a new painkiller called oliceridine for moderate to severe pain after orthopedic surgery. It may help you recover more comfortably with fewer side effects.
Yiwu, ZhejiangAges 18–100 - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+ - NCT07385131Recruiting
Steroid before infliximab for inflammatory bowel disease
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
Hangzhou, ZhejiangAges 14–80 - NCT07374471RecruitingPhase 1/Phase 2
Testing MB-001 for moderate to severe ulcerative colitis
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
ChisinauAges 18–75 - NCT06112340RecruitingPhase 2/Phase 3
Extension study of linsitinib for thyroid eye disease
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
Miami, FloridaAges 18 years+ - NCT07355075RecruitingPhase 2/Phase 3
Study of a new cream for moderate to severe eczema
This study tests an investigational cream for moderate to severe eczema. It helps see if the cream reduces symptoms like itching and skin inflammation.
Irving, TexasAges 18–80 - NCT06241482Recruiting
Enhanced recovery after brain surgery in intensive care
This study tests a special recovery program for people with serious brain injuries or strokes who need intensive care. The program focuses on helping you heal faster after surgery.
ShanghaiAges 18–75 - NCT07337434RecruitingEarly Phase 1
Comparing two pills for moderate to severe psoriasis
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Peshawar, Khyber PukhtunkhwaAges 18–60 - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT07330934RecruitingPhase 2
Study of IBI356 for moderate to severe eczema
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07326813RecruitingPhase 3
Testing D-2570 for moderate to severe plaque psoriasis
This trial tests if a new oral medication called D-2570 can safely and effectively treat moderate to severe plaque psoriasis. It may be an option if your psoriasis covers a large area and has been stable for at least 6 months.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07323654RecruitingPhase 2
Oral KT-621 for moderate to severe eosinophilic asthma
This trial tests an oral medication called KT-621 for people with moderate to severe eosinophilic asthma. It aims to see if the drug can help control asthma better than the standard inhaled treatments alone.
Lancaster, CaliforniaAges 18–75 - NCT07318688RecruitingPhase 3
Testing HMI-115 for endometriosis pain
This trial tests an experimental drug called HMI-115 to see if it reduces pain from endometriosis. If you have moderate to severe period pain and non-period pain, and you have a surgical diagnosis, you may be able to join.
Beijing, Beijing MunicipalityAges 18–49 - NCT07308834RecruitingPhase 1/Phase 2
Knee injection study for moderate to severe osteoarthritis pain
This study tests a new knee injection called CX-011 to see if it can reduce pain and improve function in people with knee osteoarthritis. It may be a good option if you have tried other treatments without enough relief.
Los Angeles, CaliforniaAges 40–75 - NCT07311369RecruitingPhase 2
Testing a new pain tablet after abdominal surgery
This trial tests a new pain tablet (HL-1186) for people having abdominal surgery. It aims to see if the tablet is safe and works well to manage pain after the operation.
Changsha, HunanAges 18–75 - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Birmingham, AlabamaAges 18–75
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.